{"entity":{"id":"pd-29875","kind":"drug","name":"225Ac/64Cu-PD-29875 (Claudin 18.2)","aka":["PD-29875"],"tldr":"225Ac/64Cu-PD-29875 (Claudin 18.2) is an experimental radioligand peptide-drug conjugate from PeptiDream, in preclinical development for gastric cancer.","summary":"225Ac/64Cu-PD-29875 (Claudin 18.2) (PD-29875) is a radioligand peptide-drug conjugate (RI-PDC) from PeptiDream. A peptide-radioisotope conjugate against Claudin 18.2, for diagnosis and treatment of gastric cancer. Its furthest stage is preclinical development, for gastric cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Pipeline lists IND-enabling for both therapeutic and diagnostic. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"PeptiDream: peptidream.com","url":"https://www.peptidream.com/en/pipeline/"},{"label":"PeptiDream: peptidream.com","url":"https://www.peptidream.com/en/pipeline/"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["cldn18-2"],"drugs":[],"companies":["peptidream"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"PD-29875","modality":"Radioligand peptide-drug conjugate (RI-PDC)","mechanism":"A peptide-radioisotope conjugate against Claudin 18.2, for diagnosis and treatment of gastric cancer.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pd-29875/","neighbours":{"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"}],"company":[{"id":"peptidream","kind":"company","name":"PeptiDream","route":"/companies/peptidream/"}]}}